You can buy or sell Baxter and other stocks, options, ETFs, and crypto commission-free!
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. Read More The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
52 Week High
52 Week Low
Yahoo FinanceMar 19
Baxter (BAX) Upgraded to Buy: Here's What You Should Know
Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Baxter International (BAX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks ...
Yahoo FinanceMar 19
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
Baxter International Inc. BAX and bioMérieux recently announced an agreement to develop future biomarkers for prompt identification and treatment of acute kidney injury (“AKI”) at the International Symposium on Intensive Care and Emergency Medicine. This is expected to boost Baxter’s Acute Therapies business apart from fortifying its foothold in the global renal care market. However, following the announcement, shares of this Zacks Rank #2 (Buy) company fell 0.2% to $76.95 at close. Details about the deal...
Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury
DEERFIELD, Ill. & MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). The announcement was made at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week. “We’re committed to improving...
Available Apr 25, Pre-Market